422 related articles for article (PubMed ID: 35458478)
1. mRNA- and Adenovirus-Based Vaccines against SARS-CoV-2 in HIV-Positive People.
Garbuglia AR; Minosse C; Del Porto P
Viruses; 2022 Apr; 14(4):. PubMed ID: 35458478
[TBL] [Abstract][Full Text] [Related]
2. Adenoviral Vector DNA- and SARS-CoV-2 mRNA-Based Covid-19 Vaccines: Possible Integration into the Human Genome - Are Adenoviral Genes Expressed in Vector-based Vaccines?
Doerfler W
Virus Res; 2021 Sep; 302():198466. PubMed ID: 34087261
[TBL] [Abstract][Full Text] [Related]
3. Comparing Immune Responses to Inactivated Vaccines against SARS-CoV-2 between People Living with HIV and HIV-Negative Individuals: A Cross-Sectional Study in China.
Huang X; Yan Y; Su B; Xiao D; Yu M; Jin X; Duan J; Zhang X; Zheng S; Fang Y; Zhang T; Tang W; Wang L; Wang Z; Xu J
Viruses; 2022 Jan; 14(2):. PubMed ID: 35215870
[TBL] [Abstract][Full Text] [Related]
4. A systems immunology study comparing innate and adaptive immune responses in adults to COVID-19 mRNA and adenovirus vectored vaccines.
Ryan FJ; Norton TS; McCafferty C; Blake SJ; Stevens NE; James J; Eden GL; Tee YC; Benson SC; Masavuli MG; Yeow AEL; Abayasingam A; Agapiou D; Stevens H; Zecha J; Messina NL; Curtis N; Ignjatovic V; Monagle P; Tran H; McFadyen JD; Bull RA; Grubor-Bauk B; Lynn MA; Botten R; Barry SE; Lynn DJ
Cell Rep Med; 2023 Mar; 4(3):100971. PubMed ID: 36871558
[TBL] [Abstract][Full Text] [Related]
5. High seroconversion rate after vaccination with mRNA BNT162b2 vaccine against SARS-CoV-2 among people with HIV - but HIV viremia matters?
Xu X; Vesterbacka J; Aleman S; Nowak P;
AIDS; 2022 Mar; 36(3):479-481. PubMed ID: 35084386
[TBL] [Abstract][Full Text] [Related]
6. Impact of the gut microbiome on immunological responses to COVID-19 vaccination in healthy controls and people living with HIV.
Ray S; Narayanan A; Vesterbacka J; Blennow O; Chen P; Gao Y; Gabarrini G; Ljunggren HG; Buggert M; Manoharan L; Chen MS; Aleman S; Sönnerborg A; Nowak P
NPJ Biofilms Microbiomes; 2023 Dec; 9(1):104. PubMed ID: 38123600
[TBL] [Abstract][Full Text] [Related]
7. Humoral immune response following prime and boost BNT162b2 vaccination in people living with HIV on antiretroviral therapy.
Jedicke N; Stankov MV; Cossmann A; Dopfer-Jablonka A; Knuth C; Ahrenstorf G; Ramos GM; Behrens GMN
HIV Med; 2022 May; 23(5):558-563. PubMed ID: 34725907
[TBL] [Abstract][Full Text] [Related]
8. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
9. Insights from the Construction of Adenovirus-Based Vaccine Candidates against SARS-CoV-2: Expecting the Unexpected.
Weklak D; Tisborn J; Mangold MH; Scheu R; Wodrich H; Hagedorn C; Jönsson F; Kreppel F
Viruses; 2023 Oct; 15(11):. PubMed ID: 38005833
[TBL] [Abstract][Full Text] [Related]
10. Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination.
Jalkanen P; Kolehmainen P; Haveri A; Huttunen M; Laine L; Österlund P; Tähtinen PA; Ivaska L; Maljanen S; Reinholm A; Belik M; Smura T; Häkkinen HK; Ortamo E; Kantele A; Julkunen I; Lempainen J; Kakkola L
Microbiol Spectr; 2022 Apr; 10(2):e0225221. PubMed ID: 35262410
[TBL] [Abstract][Full Text] [Related]
11. Distinct platelet crosstalk with adaptive and innate immune cells after adenoviral and mRNA vaccination against SARS-CoV-2.
Lombardi L; Maiorca F; Marrapodi R; Sabetta A; Scafa N; Pallucci D; Miglionico M; Romiti GF; Corica B; Piconese S; Polimeni A; Pulcinelli F; Cangemi R; Visentini M; Basili S; Stefanini L
J Thromb Haemost; 2023 Jun; 21(6):1636-1649. PubMed ID: 36918114
[TBL] [Abstract][Full Text] [Related]
12. The role of vaccination route with an adenovirus-vectored vaccine in protection, viral control, and transmission in the SARS-CoV-2/K18-hACE2 mouse infection model.
Dickson A; Geerling E; Stone ET; Hassert M; Steffen TL; Makkena T; Smither M; Schwetye KE; Zhang J; Georges B; Roberts MS; Suschak JJ; Pinto AK; Brien JD
Front Immunol; 2023; 14():1188392. PubMed ID: 37662899
[TBL] [Abstract][Full Text] [Related]
13. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC].
Poh XY; Lee IR; Lim C; Teo J; Rao S; Chia PY; Ong SWX; Lee TH; Lin RJH; Ng LFP; Ren EC; Lin RTP; Wang LF; Renia L; Lye DC; Young BE
Trials; 2022 Jun; 23(1):498. PubMed ID: 35710572
[TBL] [Abstract][Full Text] [Related]
15. Anti-SARS-CoV-2 IgA and IgG in human milk after vaccination is dependent on vaccine type and previous SARS-CoV-2 exposure: a longitudinal study.
Selma-Royo M; Bäuerl C; Mena-Tudela D; Aguilar-Camprubí L; Pérez-Cano FJ; Parra-Llorca A; Lerin C; Martínez-Costa C; Collado MC
Genome Med; 2022 Apr; 14(1):42. PubMed ID: 35449030
[TBL] [Abstract][Full Text] [Related]
16. Effects of BNT162b2 Messenger RNA Vaccine and ChAdOx1 Adenovirus Vector Vaccine on Deaths From COVID-19 in Adults Aged ≥70 Years.
Lopez Bernal J; Andrews N; Gower C; Stowe J; Tessier E; Simmons R; Ramsay M
Clin Infect Dis; 2024 Feb; 78(2):349-351. PubMed ID: 37758203
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study.
Furer V; Eviatar T; Zisman D; Peleg H; Paran D; Levartovsky D; Zisapel M; Elalouf O; Kaufman I; Meidan R; Broyde A; Polachek A; Wollman J; Litinsky I; Meridor K; Nochomovitz H; Silberman A; Rosenberg D; Feld J; Haddad A; Gazzit T; Elias M; Higazi N; Kharouf F; Shefer G; Sharon O; Pel S; Nevo S; Elkayam O
Ann Rheum Dis; 2021 Oct; 80(10):1330-1338. PubMed ID: 34127481
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV.
Vergori A; Cozzi Lepri A; Cicalini S; Matusali G; Bordoni V; Lanini S; Meschi S; Iannazzo R; Mazzotta V; Colavita F; Mastrorosa I; Cimini E; Mariotti D; De Pascale L; Marani A; Gallì P; Garbuglia A; Castilletti C; Puro V; Agrati C; Girardi E; Vaia F; Antinori A;
Nat Commun; 2022 Aug; 13(1):4922. PubMed ID: 35995780
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study.
Fabiani M; Puopolo M; Morciano C; Spuri M; Spila Alegiani S; Filia A; D'Ancona F; Del Manso M; Riccardo F; Tallon M; Proietti V; Sacco C; Massari M; Da Cas R; Mateo-Urdiales A; Siddu A; Battilomo S; Bella A; Palamara AT; Popoli P; Brusaferro S; Rezza G; Menniti Ippolito F; Pezzotti P;
BMJ; 2022 Feb; 376():e069052. PubMed ID: 35144968
[TBL] [Abstract][Full Text] [Related]
20. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
